Nuclea Biotechnologies signed an R&D agreement with Berkshire Medical Center (BMC) that could lead to more effective treatment for prostate and breast cancer. This partnership will advance R&D biomarkers, which are a vital component in the field of personalized medicine.
Nuclea discovers and develops biomarkers (genes, proteins, and antibodies) and diagnostic assays that help predict which treatments will be effective for different patients, depending on their genetic makeup. With individual patient consent, this agreement allows BMC to provide Nuclea with samples of serum and tumor tissue for the purpose of identifying biomarkers for cancer diagnostics.
"For the oncologists in our community, it is critical that they have access to the latest research and treatment options to help our patients achieve the best outcomes," said David Phelps, president and chief executive officer of BHS.